Erik S. Mittra
A Stanford-trained nuclear medicine doctor who leads the theranostics programme at Oregon Health & Science University and treats neuroendocrine tumour patients with radioactive peptide therapy.
Overview
Erik Mittra trained through the MD/PhD programme at Stony Brook University and completed nuclear medicine residency and PET/CT fellowship at Stanford, where he was faculty for eight years before joining Oregon Health & Science University (OHSU) in 2018. He is now Chief of Nuclear Medicine and Molecular Imaging and Director of Radiopharmaceutical Therapeutics at OHSU, running its multidisciplinary neuroendocrine tumour treatment programme.
His research focuses on peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE, including as a co-author on the substudy dosimetry analysis of the pivotal NETTER-1 trial, and on 90Y radioembolisation dosimetry using fused MAA-SPECT imaging. He has published extensively on FDG and NaF PET applications in oncology dating back to his Stanford years.
| Title | Journal | Year |
|---|---|---|
| Dosimetry of [177Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial | Journal of Nuclear Medicine | 2025 |
| Prognostic Utility of 90Y Radioembolization Dosimetry Based on Fusion 99mTc-Macroaggregated Albumin-99mTc-Sulfur Colloid SPECT | Journal of Nuclear Medicine | 2013 |
Similar pages
not linked directly; found by shared links- PersonLisa Bodei
Shares NETTER-1, Peptide receptor radionuclide therapy (PRRT), Lutetium-177 dotatate, Lutetium-177 and the tags neuroendocrine, PRRT, clinician.
- Key paperHealth-related quality of life in the NETTER-1 trial of 177Lu-Dotatate
Shares NETTER-1, Peptide receptor radionuclide therapy (PRRT), Lutetium-177 dotatate, Lutetium-177 and the tag PRRT.
- TermRenal protection with amino acid co-infusion
Shares Yttrium-90, Peptide receptor radionuclide therapy (PRRT), Lutetium-177 dotatate, Lutetium-177 and the tag PRRT.
- Key paperResults and adverse events of personalised peptide receptor radionuclide therapy in 1048 patients with neuroendocrine neoplasms
Shares Yttrium-90, Peptide receptor radionuclide therapy (PRRT), Lutetium-177 dotatate, Lutetium-177 and the tag PRRT.
- TermFixed versus personalised (dosimetry-guided) dosing
Shares Yttrium-90, Peptide receptor radionuclide therapy (PRRT), Lutetium-177 dotatate, Lutetium-177 and the tag PRRT.
- TechnologySPECT dosimetry workflow for radionuclide therapy
Shares Yttrium-90, Peptide receptor radionuclide therapy (PRRT), Lutetium-177 and the tag PRRT.
- CompanyMolecular Targeting Technologies
Shares Peptide receptor radionuclide therapy (PRRT), Lutetium-177 dotatate, Lutetium-177 and the tag PRRT.
- IsotopeScandium-47
Shares Peptide receptor radionuclide therapy (PRRT), Lutetium-177.